Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

American Society Of Clinical Oncology (ASCO) 2017 Annual Meeting is organized by American Society Of Clinical Oncology (ASCO) and will be held on June 2 -6, 2017 at McCormick Place in Chicago. The conference program offers informative educational and scientific sessions on the latest cancer care treatments.

ASCO 2017

02–06 June 2017 | Chicago, USA

ASCO 2017

02–06 June 2017 | Chicago, USA

American Society Of Clinical Oncology (ASCO) 2017 Annual Meeting is organized by American Society Of Clinical Oncology (ASCO) and will be held on June 2 -6, 2017 at McCormick Place in Chicago. The conference program offers informative educational and scientific sessions on the latest cancer care treatments.

Richter’s syndrome and its impact on CLL patients 2:08
Richter’s syndrome and its impact on CLL patients
Matthew Davids • 1 Jun 2017
Immune checkpoint inhibitors and their role in MM: pembrolizumab and durvalumab 1:32
Immune checkpoint inhibitors and their role in MM: pembrolizumab and durvalumab
Maria-Victoria Mateos • 1 Jun 2017
A follow-up from the CASTOR trial evaluating daratumumab with bortezomib for the treatment of MM 2:09
A follow-up from the CASTOR trial evaluating daratumumab with bortezomib for the treatment of MM
Maria-Victoria Mateos • 1 Jun 2017
SWOG S0777 trial: lenalidomide, dexamethasone and bortezomib for the treatment of MM 2:34
SWOG S0777 trial: lenalidomide, dexamethasone and bortezomib for the treatment of MM
Maria-Victoria Mateos • 1 Jun 2017
Is the CR of MM patients a good objective for treatment? 0:50
Is the CR of MM patients a good objective for treatment?
Maria-Victoria Mateos • 1 Jun 2017
Individualising treatment for elderly MM patients 0:56
Individualising treatment for elderly MM patients
Maria-Victoria Mateos • 1 Jun 2017
Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients? 3:29
Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?
Susan O’Brien • 1 Jun 2017
Ponatinib and its role in treating ALL 2:50
Ponatinib and its role in treating ALL
Susan O’Brien • 1 Jun 2017
What is the future of treating ALL? 3:30
What is the future of treating ALL?
Susan O’Brien • 1 Jun 2017
FCR or FR – which regimen is better for treating CLL? 2:01
FCR or FR – which regimen is better for treating CLL?
Susan O’Brien • 1 Jun 2017
Why do many MM patients relapse after being treated with targeted therapy? 1:56
Why do many MM patients relapse after being treated with targeted therapy?
Gareth Morgan • 1 Jun 2017
What is the best treatment regimen for MM? 6:13
What is the best treatment regimen for MM?
Laurent Garderet • 1 Jun 2017
An overview of the potential of immunotherapy in treating lymphoma 3:34
An overview of the potential of immunotherapy in treating lymphoma
Anas Younes • 1 Jun 2017
iFCG: a promising new regimen for treating IGHV-mutated CLL 1:35
iFCG: a promising new regimen for treating IGHV-mutated CLL
Nitin Jain • 2 Jun 2017
Lenalidomide and ibrutinib: do they have a future in treating CLL? 1:08
Lenalidomide and ibrutinib: do they have a future in treating CLL?
Nitin Jain • 2 Jun 2017
Prospects of treating CLL and their complications 1:36
Prospects of treating CLL and their complications
Nitin Jain • 2 Jun 2017

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals